TEsting METformin Against Cognitive Decline in HD

March 29, 2022 updated by: Instituto de Investigacion Sanitaria La Fe

"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease.

The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up visit (one month after the end of treatment).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of treatment with metformin at a dose of 1700 mg / day in adults with HD.

A total recruitment of 60 patients is expected, which will be randomized in a 1: 1 ratio. 30 patients will receive metformin 1700 g / day, or placebo, for 52 weeks.

Patients will begin taking low doses of metformin, to facilitate tolerance and decrease intestinal discomfort. Half the daily dose (425 mg twice daily) will be administered over four weeks, along with the main meals. Patients who tolerate this dose well will continue with treatment by taking 850mg twice daily. Patients who don´t tolerate the initial dose (425 mg twice daily) will be withdrawn from the study.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Spain
      • Barcelona, Spain, 08035
        • Recruiting
        • Unitat Polivalent Barcelona Nord
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramón y Cajal
    • Alicante
      • Elche, Alicante, Spain, 03203
        • Recruiting
        • Hospital General Universitario de Elche
    • Castilla La Mancha
      • Albacete, Castilla La Mancha, Spain, 02006
        • Recruiting
        • Complejo Hospitalario de Albacete
    • Castilla Y León
      • Burgos, Castilla Y León, Spain, 09006
        • Recruiting
        • Hospital Universitario Burgos
    • Islas Baleares
      • Palma De Mallorca, Islas Baleares, Spain, 07120
        • Recruiting
        • Hospital Universitari Son Espases
    • Principado De Asturias
      • Oviedo, Principado De Asturias, Spain, 33011
        • Recruiting
        • Hospital Universitario Central de Asturias
    • València
      • Valencia, València, Spain, 46026
        • Recruiting
        • Hospital Universitario y Politecnico La Fe

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Symptomatic positive clinical diagnosis of Huntington disease.
  2. Presence of 36 CAG repeats (or more) in the hunting gene based on centralized CAG analysis.
  3. Men or women between 21-65 years of age, inclusive, with an onset of HD at 18 years of age or older.
  4. Women of childbearing potential (women who are not postmenopausal children or who have not undergone surgical sterilization at times) will need to be using a contraceptive method for 30 days before beginning study treatment, and will have contact with at least two methods of birth control throughout the duration of the study and up to 30 days after taking the last dose of treatment.
  5. A sum of > 4 points on the UHDRS-TMS scale and a diagnostic confidence level of 4.
  6. Scale of independence ≥ 75%.
  7. Score on the UHDRS-TFC scale ≥ 8 at the screening visit.
  8. They must be trained and willing to provide written informed consent prior to any procedure related to the study to be performed at the screening visit. Patients with a legal guardian must be determined according to local requirements.
  9. They must be trained and will require taking oral medication and will need to be determined to comply with the specific study procedures.
  10. They must be able to travel to the study center and, in the judgment of the investigator, demonstrate that it is probable that they can continue traveling during the study.
  11. Availability and willingness of a caregiver, informant, or family member to provide information during study visits that evaluate PBA-s. It is recommended that the caregiver be someone who cares for the patient at least 2 to 3 times a week and at least 3 hours per occasion. The suitability of the caregiver must be judged by the investigator.

Exclusion Criteria:

  1. The participant has taken metformin in the last three months before the start of the study.
  2. The participant has diabetes of any kind.
  3. The participant is pregnant or lactating.
  4. The participant has a medical condition other than HD (metabolism, kidney function, liver function, heart problems, etc.), or any contraindication against metformin.
  5. The participant has an uncontrolled psychiatric condition.
  6. Participant is allergic to metformin or any of the other ingredients of this medicine.
  7. The participant has kidney problems [creatinine clearance <60 ml / min calculated using Cockcroft-Gault formula] or liver problems.
  8. The participant is dehydrated, from prolonged or severe diarrhea, or has vomited several times.
  9. The participant has a serious infection.
  10. The participant has been treated for heart failure or has recently had a heart attack, has severe circulation problems, or is having difficulty breathing.
  11. The participant drinks> 6 units / day of alcohol (alcoholism).
  12. Participants diagnosed with oncological disease.
  13. Participants with a suicidal propensity, with an affirmative answer in items 4 or 5 in the C-SSRS at the screening visit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Metformin
Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
Drug: Metformin
Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
Other Names:
  • Biguanides (oral antidiabetic)
Placebo Comparator: Placebo
Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
Drug: Placebo
425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
Other Names:
  • Not appicable

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the effect of metformin on the scores obtained in different cognitive subtests that make up the Unified Huntington's Disease Rating Scale
Time Frame: Baseline - Week 52

The tests that make up this subscale are the Symbol Digit Modalities Test.

It is a comparative test that is collected throughout the entire trial to assess the progression of cognitive functions in patients.

The test has 90 seconds time limit.
Baseline - Week 52
Evaluate the effect of metformin on the scores obtained in different cognitive subtests that make up the Unified Huntington's Disease Rating Scale (UHDRS).
Time Frame: Baseline - Week 52

The tests that make up this subscale are the verbal fluency under phonetic slogan with the letters F, A and S,

It is a comparative test that is collected throughout the entire trial to assess the progression of cognitive functions in patients.

It consists of four categories of time 0-15; 16-30; 31-45 and 46-60 seconds and both hits and errors are counted.
Baseline - Week 52
Evaluate the effect of metformin on the scores obtained in different cognitive subtests that make up the Unified Huntington's Disease Rating Scale (UHDRS).
Time Frame: Baseline - Week 52

The tests that make up this subscale are words and interference in the Stroop test.

The Stroop test was performed to determine selective attention and inhibitory response (selective response to stimuli) to recognize a different stimulus among others. The test involves three kinds of stimuli: three columns of color names printed in black (condition A), three columns with different colors (red, green, blue or black) (condition B), and three columns of color names printed in a color that does not necessarily correspond to the word (for For example, the word "green" printed in blue, (condition C). The 3 parts of the test consist of A. speed of reading the words (names of colors printed in black), B. speed of nomination, the subject must name the colors. C. inhibitory response, called the interference test, where the subject must name the color in which the word with the name of the other color.

The test has 45 seconds time limit.
Baseline - Week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the effect of metformin on motor function in patients with Huntington's disease using the Unified Huntington's Disease Scale Total Motor Score.
Time Frame: Baseline - Visit 1 (Week 0) - Week 26 - Week 52

The motor function evaluation will include the following exams:

Ocular Pursuit (horizontal and vertical), Saccade Initiation (horizontal and vertical), Saccade Velocity (horizontal and vertical), Dystrary, Lingual Protusion, Distonia (trunk and limbs), Korea (face , Mouth, trunk and extremities), Repulsion Test, Finger Tast (right and left), Pronate/ Supinate-Hands (right and left), Luria (palm test), Arm rigidity (right and left), Brady Kinesia-Body, Gait (walking difficulties), Tandem Walking.

The initial stage of Huntington's Disease is related to a score greater than 4 on the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS) and a total functional capacity (UHDRS-TFC) greater than 8.
Baseline - Visit 1 (Week 0) - Week 26 - Week 52
Evaluate the effect of metformin on functional capacity in patients with Huntington´s disease using Unified Huntington's Disease Scale Functional Capacity.
Time Frame: Baseline - Visit 1 (Week 0) - Week 26 - Week 52

It is evaluated by means of a questionnaire on the following variables:

Occupation, Finance, Daily life activities, Domestic Works Level of Care.

The initial stage of Huntington's Disease is related to a score greater than 4 on the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS) and a total functional capacity (UHDRS-TFC) greater than 8.

Where 0 its de worse situation and 3 its normal situation
Baseline - Visit 1 (Week 0) - Week 26 - Week 52
Evaluate the effect of metformin on behavioral signs and symptoms in patients with Huntington´s disease using Problem Behaviors Assessment-Short form (PBA-s)
Time Frame: Baseline - Visit 1 (Week 0) - Week 26 - Week 52

Specifically, will be evaluated on the changes in severity obtained in the items of depressed mood, suicidal ideation, anxiety, irritability, aggressiveness, apathy, persistent behavior and thinking, obsessive-compulsive behavior, delusional ideation, hallucinations, and disorientation.

The severity is scored is the 0 (absent) to 4 (severe; almost unbearable for the caregiver) The frequency is scored is the 0 (never / almost never) to 4 (daily / almost daily most of the day)
Baseline - Visit 1 (Week 0) - Week 26 - Week 52
Evaluate if there are genetic markers associated to metformin by analysis pharmacogenetic.
Time Frame: Visit 1 (week 0)
Analyze whether there are genetic markers associated with a better (or worse) response to metformin, through pharmacogenetics. The genotype of the patients will be analyzed on this material in a panel of single nucleotide polymorphisms (SNPs), related to the effect of Metformin and other medications that patients may be taking simultaneously.
Visit 1 (week 0)
Analyze the light chain protein of neurofilaments in peripheral blood.
Time Frame: Visit 1 (week 0) and Visit 8 (Week 56)
Analyze the light chain protein of neurofilaments in peripheral blood, as a circulating biomarker. Biomarker analysis will consist of obtaining information on the concentrations of various proteins, which tend to be released into the bloodstream when there are lesions in the nervous system.
Visit 1 (week 0) and Visit 8 (Week 56)
Evaluate the effect of metformin on the degree of independence in patients with Huntington's disease using the Unified Huntington's Disease Rating Scale Functional assessment and independence assessment.
Time Frame: Baseline - Visit 1 (Week 0) - Week 26 - Week 52
The scale consists in two parts. The first part is to make a functional evaluation with scored is 0 or 1. The second part evaluate degree of independence with scored the 5% to 100%.
Baseline - Visit 1 (Week 0) - Week 26 - Week 52
Evaluate the effect of metformin in patients body with Huntington's disease.
Time Frame: Baseline to Week 52

Incidence of adverse events and incidence of abnormal laboratory test results,

The classification of adverse events will be mild, moderate and serious by medical criteria.
Baseline to Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Instituto de Investigacion Sanitaria La Fe

Investigators

  • Study Chair: Carmen Peiró, Phd, MD, Instituto de Investigación Sanitaria La Fe

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2021

Primary Completion (Anticipated)

August 1, 2024

Study Completion (Anticipated)

August 1, 2024

Study Registration Dates

First Submitted

September 15, 2020

First Submitted That Met QC Criteria

March 29, 2021

First Posted (Actual)

April 1, 2021

Study Record Updates

Last Update Posted (Actual)

April 7, 2022

Last Update Submitted That Met QC Criteria

March 29, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TEMET-HD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Huntington Disease

Clinical Trials on Metformin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe